The makers of popular weight-loss drugs Wegovy and Ozempic, Novo Nordisk, are taking legal action against a rival company, Hims & Hers, over their 'knock-off' versions of these medications. The Danish pharmaceutical giant is seeking a court-issued ban on Hims & Hers' weight-loss pills and injections, which it claims are unsafe and infringe on its patents. This lawsuit comes as a response to Hims & Hers' recent launch of a new weight-loss pill, which Novo Nordisk views as a direct competitor. The legal drama unfolded over the weekend, with Hims & Hers initially threatening to continue selling the pill, leading to a 16% drop in their stock price on Monday. In contrast, Novo Nordisk's shares rose early on Tuesday as the company pressed ahead with its lawsuit, citing concerns over the safety and efficacy of Hims & Hers' compounded drugs. The controversy revolves around the legal process of compounding, where drug makers can sell unapproved medications to patients with specific needs. Novo Nordisk argues that Hims & Hers' compounded drugs may contain dangerous impurities or incorrect dosages, posing serious health risks. This is not the first time Novo Nordisk has faced regulatory scrutiny, as the FDA recently criticized the company for misleading advertisements, suggesting benefits beyond physical weight loss. The company is now navigating a complex legal battle, balancing its desire to protect public health with the need to respect consumer choice and the principles of compounding.
